Omeros Corporation (OMER) Q3 Net Loss $57.4M; YARTEMLEA Net Revenue Rose 26%
Omeros reported Q3 2026 net revenue of $35.9M for YARTEMLEA, a 26% increase from Q2, and a GAAP net loss of $57.4M. The loss included a $62.0M non-cash charge, while operating cash flow was $13.3M. The company is in the early commercial stage, with revenue growth and positive cash flow alongside pipeline investment.
How this was made

The 30-second read
Why it matters
For trading, the key tension is improving sequential product revenue versus continued GAAP losses, with operating cash flow offering some support to the commercial-ramp thesis.
Market read
This is a company-specific quarterly update with concrete revenue and loss figures that can shift near-term positioning in Omeros.
What to watch
Traders may focus on whether operating cash flow can sustain while pipeline investment continues, but the article provides no guidance or forward milestones beyond the sequential revenue change.
Background
The piece summarizes Omeros’ Q3 2026 performance, highlighting YARTEMLEA revenue growth and ongoing pipeline investment.
Ticker impact
Omeros reports Q3 2026 YARTEMLEA net revenue of $35.9M (+26% sequential) alongside a GAAP net loss of $57.4M.
Likely mixed reaction, with traders weighing revenue momentum against continued heavy losses and cash burn optics.
The article provides both the revenue growth datapoint and the magnitude of the GAAP loss/non-cash charge, which typically drives near-term sentiment in early commercial-stage biotech/pharma.
Market effects
Reinforces the narrative that early commercial-stage specialty pharma can show sequential revenue growth while still carrying large accounting losses.
No clear regional spillover beyond US small/mid-cap biotech sentiment.
Limited, as the update is company-specific with no broader macro or cross-border catalyst described.
Counterpoint
The GAAP loss is heavily driven by a $62.0M non-cash charge, so the market may over-penalize accounting losses versus the $13.3M operating cash flow.
Key entities
- companyOmeros Corporation
Reports Q3 2026 YARTEMLEA net revenue growth and a GAAP net loss, including a large non-cash charge.
- productYARTEMLEA
Omeros’ product whose Q3 net revenue rose 26% sequentially to $35.9M.

